Abstract

Although much of the recent progress in managing metastatic castration-resistant prostate cancer (mCRPC) is based on targeting the androgen receptor,

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call